Latigo Biotherapeutics, Inc. LTGO

Annual Quarterly

No quarterly revenue total was found in Latigo Biotherapeutics, Inc.'s SEC filings.

Latigo Biotherapeutics, Inc. (LTGO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$19.6 million. As of Sep 30, 2026 it held $401.2 million in cash and investments and $1.2 million in total debt.

Revenue
—
Net income
$-20.95M
+18.8% vs prior quarter
Operating cash flow
$-19.52M
+59.6% vs prior quarter
Free cash flow
$-19.56M
+59.6% vs prior quarter
EPS
$-0.55
+98.0% vs prior quarter
Dividend per share
$0.00
Shares outstanding
66.30M
+0.0% vs prior quarter
Net cash
$400.05M
Q3 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LTGO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Thousand Oaks, CA
SEC filer status
, Emerging growth company
SEC CIK
2056611

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Operating income
-$22.9M
-$25.8M
Net income
-$20.9M
-$25.8M
Diluted EPS
-$0.55
-$27.59
Operating cash flow
-$19.5M
-$48.4M
Free cash flow
-$19.6M
-$48.5M
Total assets
$408.5M
$64.8M
Total liabilities
$14.5M
$52.3M
Stockholders' equity
$394.0M
-$276.1M
Cash and investments
$401.2M
$55.0M
Total debt
$1.2M
$1.4M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 5, 2026 Sep 30, 2026
8-K Current report
Results of operations, Officer or director change
 Nov 5, 2026 Nov 3, 2026
10-Q Quarterly report Sep 3, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Sep 3, 2026 Sep 3, 2026
8-K Current report
Bylaw or fiscal year change, Other events
 Aug 10, 2026 Aug 10, 2026

All 43 Latigo Biotherapeutics, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.